A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
about
Nucleic acid aptamers: research tools in disease diagnostics and therapeuticsAnimal models for thrombotic thrombocytopenic purpuraDNA Aptamers in the Diagnosis and Treatment of Human DiseasesRNA plasticity and selectivity applicable to therapeutics and novel biosensor developmentInherited thrombocytopenias: an approach to diagnosis and management.Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIbα interaction.Potential capacity of aptamers to trigger immune activation in human blood.Translation and Clinical Development of Antithrombotic Aptamers.DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice.Aptamers as both drugs and drug-carriers.Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE.Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.
P2860
Q26824321-28184D99-41D9-481E-AF0B-BF7CEB8307A7Q26851228-C7C8EEC6-5D32-49B4-9161-FD1005372D6DQ26864314-55115CE0-4584-49A3-BF64-6143492FE6FCQ28727743-66938190-0B8E-43B2-8E8C-41AD47B3884EQ33402583-BFCD77A1-4A42-4863-982B-B826B82B26D6Q33403225-4CA0F59D-E459-4558-8D67-4BB0FA3D2D38Q33419324-E30C410E-9C38-4F34-B1CD-87636C0A6343Q33423350-C11945CA-D7E2-470B-A03C-D7339E4E49B3Q34448727-81C21986-0295-4AA0-9C24-48101FCF33E9Q34918601-0E0BF399-1B98-4A67-86BB-0EBD48B04E15Q36987361-1E324D99-03DA-46C5-9EF5-68435E718949Q37110641-4978869E-6181-43B0-8E99-23583A7FFF71Q38058760-1F5E327A-D5DB-42A1-8CE1-8CF75418F9BAQ39025239-91E1D528-8683-430C-ABE9-F4B381DEB77CQ42236644-EF84F65C-2C2A-4D31-9E1D-68AB07854904Q43111677-A84BFDB3-5923-46A7-A5DD-76EA75C938B8Q51202855-8DF95983-68A2-42F4-A512-6F99A4B09A5BQ51685125-BBEC57B3-1DA1-426D-9794-E71AD9927933Q54335457-DAC6E076-875D-4D71-AFF8-6EBC2C37B8CD
P2860
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@ast
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@en
type
label
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@ast
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@en
prefLabel
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@ast
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@en
P2093
P921
P356
P1476
A dose ranging phase I/II tria ...... otic thrombocytopenic purpura.
@en
P2093
Bernd Jilma
James C Gilbert
Monika E Gorczyca
Paul Knöbl
P304
P356
10.1160/TH11-02-0069
P577
2011-08-11T00:00:00Z